About AbTis
AbTis is a company based in Suwon (South Korea) founded in 2016 by Sang Jeon Chung. AbTis has raised $4.5 million across 1 funding round from investors including JX Partners, Stonebridge Capital and K2 Investment Partners. AbTis operates in a competitive market with competitors including Sino Biological, GenScript, Mabtech, Y-Biologics and Epitomics, among others.
- Headquarter Suwon, South Korea
- Founders Sang Jeon Chung
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.5 M (USD)
in 1 rounds
-
Latest Funding Round
$4.5 M (USD), Seed
Jun 01, 2018
-
Investors
JX Partners
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AbTis
AbTis has successfully raised a total of $4.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $4.5 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AbTis
AbTis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include JX Partners, Stonebridge Capital and K2 Investment Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Early-stage tech and life sciences focused VC & PE firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for AbTis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AbTis
Investment portfolio details for AbTis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AbTis
Detailed financials for AbTis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abtis Comparisons
Peer comparison for AbTis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AbTis
AbTis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sino Biological, GenScript, Mabtech, Y-Biologics and Epitomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Antibodies and immunoassay kits are developed for research applications.
|
|
| Locked | Locked | Locked |
Developer of antibodies for the treatment of multiple diseases
|
|
| Locked | Locked | Locked |
Monoclonal antibody technology and products are developed by Epitomics.
|
|
| Locked | Locked | Locked |
Antibody and vaccine culture media products are developed.
|
Detailed competitors of AbTis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abtis
Complete news archive for AbTis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AbTis
AbTis was founded in 2016 and raised its 1st funding round 2 years after it was founded.
AbTis is headquartered in Suwon, South Korea. It is registered at Suwon, Gyeonggi, South Korea.
Sang Jeon Chung is the current CEO of AbTis. They have also founded this company.
AbTis is a funded company, having raised a total of $4.5M across 1 funding round to date.
AbTis was founded in 2016 in Suwon-si, South Korea, where operations focus on biotechnology for antibody-drug conjugates. Proprietary technologies, including the AbTis linker for site-specific binding and AbTis Michelle for drug solubility, are offered. The pipeline also encompasses monoclonal antibody drug conjugates. Leadership is provided by founder and CEO Sang Jeon Chung.
AbTis's top competitors include Sino Biological, GenScript and Y-Biologics.
AbTis has 3 investors. Key investors include JX Partners, Stonebridge Capital, and K2 Investment Partners.